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Abstract 
The UDP-glucuronosyltransferases (UGTs) are enzymes of the phase II metabolic system. 
These enzymes catalyze the transfer of α-D-glucuronic acid from UDP-glucuronic acid to 
aglycones bearing nucleophilic groups affording exclusively their corresponding β-D-
glucuronides to render lipophilic endobiotics and xenobiotics more water soluble. This 
detoxification pathway aids in the urinary and biliary excretion of lipophilic compounds thus 
preventing their accumulation to harmful levels. 
 
The aim of this study was to investigate the effect of stereochemical and steric features of 
substrates on the glucuronidation catalyzed by UGTs 2B7 and 2B17. Furthermore, this study 
relates to the design and synthesis of novel, selective inhibitors that display high affinity for 
the key enzyme involved in drug glucuronidation, UGT2B7. 
 
The starting point for the development of inhibitors was to assess the influence of the 
stereochemistry of substrates on the UGT-catalyzed glucuronidation reaction. A set of 28 
enantiomerically pure alcohols was subjected to glucuronidation assays employing the 
human UGT isoforms 2B7 and 2B17. Both UGT enzymes displayed high stereoselectivity, 
favoring the glucuronidation of the (R)-enantiomers over their respective mirror-image 
compounds. The spatial arrangement of the hydroxy group of the substrate determined the 
rate of the UGT-catalyzed reaction. However, the affinity of the enantiomeric substrates to 
the enzymes was not significantly influenced by the spatial orientation of the nucleophilic 
hydroxy group. 
 
Based on these results, a rational approach for the design of inhibitors was developed by 
addressing the stereochemical features of substrate molecules. Further studies showed that 
the rate of the enzymatic glucuronidation of substrates was also highly dependent on the 
steric demand in vicinity of the nucleophilic hydroxy group. These findings provided a rational 
approach to turn high-affinity substrates into true UGT inhibitors by addressing 
stereochemical and steric features of substrate molecules. 
 
The tricyclic sesquiterpenols longifolol and isolongifolol were identified as high-affinity 
substrates which displayed high selectivity for the UGT isoform 2B7. These compounds 
served therefore as lead structures for the design of potent and selective inhibitors for 
UGT2B7. Selective and potent inhibitors were prepared by synthetically modifying the lead 
compounds longifolol and isolongifolol taking stereochemical and steric features into 
account. The best inhibitor of UGT2B7, β-phenyllongifolol, displayed an inhibition constant of 
0.91 nM. 
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Abbreviations 
[I]  inhibitor concentration 
[S]  substrate concentration 
2B7CT  cofactor-binding domain of UGT2B7 
3α-DIOL androstane-3α,17β-diol 
α  modifying factor 
ADT  androsterone 
AICC  corrected Akaike‟s information criterion 
ASBT  apical sodium-dependent bile acid transporter 
AUC  area under the concentration-time curve for uninhibited metabolism 
AUCi  area under the concentration-time curve for inhibited metabolism 
AZT  3‟-azido-3‟-deoxythymidine, zidovudine 
CES  carboxylesterases 
CN-I  Crigler-Najjar syndrome type I 
CN-II  Crigler-Najjar syndrome type II 
CoMFA comparative molecular field analysis 
ΔAICC  difference in AICC values for two competing models 
DEANB  borane N,N-diethylaniline complex 
DHT  dihydrotestosterone 
DMEs  drug metabolizing enzymes 
DMSO  dimethylsulfoxide 
ER  endoplasmic reticulum 
FDA  US Food and Drug Administration 
GI  gastrointestinal 
GlcA  glucuronic acid 
h  Hill coefficient 
IBX  2-iodoxybenzoic acid 
IC50  concentration of inhibitor which causes 50% inhibition 
K  number of parameters in the respective inhibition model 
Ki  inhibition constant 
Kic  competitive inhibition constant 
Kim  mixed-type inhibition constant 
Kin  noncompetitive inhibition constant 
Kiu  uncompetitive inhibition constant 
Km  Michaelis constant 
M3G  morphine-3-glucuronide 
M6G  morphine-6-glucuronide 
N  number of data points 
N-OH-AAF N-hydroxy-2-acetylaminofluorene 
non-HDL  non-high density lipoprotein 
NSAID s nonsteroidal anti-inflammatory drugs 
QSAR  quantitative structure-activity relationship 
SAR  structure-activity relationship 
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SN2  bimolecular nucleophilic substitution 
T3  3,3‟,5-triiodothyronine 
TPEU  2,2,2-triphenylethyl-UDP 
TS  transition state 
SN-38  7-ethyl-10-hydroxycamptothecin 
SN-38G 7-ethyl-10-hydroxycamptothecin-β-D-glucuronide 
SNP  single nucleotide polymorphism 
SS  absolute sum of squares 
UDP  uridine 5‟-diphosphate 
UDPGlcA UDP-glucuronic acid 
UGT  UDP-glucuronosyltransferase; UDP-glycosyltransferase 
UGT  UGT gene 
UMP  uridine 5‟-monophosphate 
v0  velocity of uninhibited enzymatic glucuronidation 
vi  velocity of inhibited enzymatic glucuronidation 
Vmax  maximum velocity 
VvGT1  plant flavonoid glucosyltransferase 
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1. Introduction 
The stereochemistry of chiral endobiotics and xenobiotics frequently influences their 
pharmacodynamic, pharmacokinetic, and toxicological profiles (Crossley, 1995; Eichelbaum, 
2003). These differences are based on the distinct interactions between chiral entities and 
the homochiral functional constituents of the human body such as receptors, enzymes, and 
transport proteins. In recent years, the advent of efficient asymmetric synthesis enabling the 
production of single-enantiomer entities at high optical purities together with progresses in 
the development of efficient purification and analytical methods for chiral compounds have 
paved the way for investigations on the stereoselective outcomes of chiral interactions in the 
organism (Federsel, 2005). In drug design and development, these advances resulted in the 
development of optically pure drugs by neglecting the non-active, less active, or even toxic 
stereoisomeric “ballast” (Ariëns, 1984). Detailed insights into stereoselective pharmacological 
events have led to the understanding that single-enantiomer drugs are often superior over 
the administration of isomeric mixtures and, therefore, new chiral drugs are approved today 
virtually exclusively as enantiopure entities (Agranat, 2002). It is therefore important to 
identify biochemical pathways in the human organism susceptible to stereoselective events 
such as the metabolism by UDP-glucuronosyltransferases (UGTs, EC 2.4.1.17), involved in 
the deactivation, activation and toxication of chiral compounds. 
 
Enzymatic glucuronidation is one of the main metabolic pathways for the detoxification of 
1 in 10 of the top 200 prescribed drugs (Williams, 2004). Perhaps the most important UGT in 
drug glucuronidation is UGT2B7 whose activity may account for the transformation of 40% of 
drugs that are metabolized by UGT isoforms (Burchell, 2005). In contrast, the human UGT 
isoform 2B17 plays only a minor role in the biotransformation of drugs (Turgeon, 2003). 
However, both isoforms UGT2B7 and 2B17 have been recognized to be involved in the 
inactivation of endogenous androgens (Bélanger, 2003). 
 
Some inhibitors of UGT enzymes have been reported, but most of them lack desirable 
levels of isoform-selectivity and potency (Grancharov, 2001). Although transition state (TS) 
analogues for UGTs have been proposed (Timmers, 1997; Noort, 1991), they did not display 
the high potency that is generally associated with TS mimics (Schramm, 2005). Furthermore, 
to pursue the design of potent and selective inhibitors for UGT enzymes merely by attaching 
a UDP-like entity to a lipophilic moiety has been rather unsuccessful. Other attempts were 
driven by random-screening of commercially available compounds and one screening 
approach led to the discovery of a potentially isoform-selective inhibitor of UGT1A4 
(Uchaipichat, 2006). Approaches to develop inhibitors for UGT enzymes based on rational 
design have been rarely conducted. 
 
Isoform-selective and potent inhibitors for UGTs and other metabolic enzymes are 
valuable tools for pharmacokinetic studies in drug design and development. They facilitate 
the identification of enzymes that are responsible for drug metabolism and can be applied to 
testing in tissue preparations. Furthermore, selective inhibitors can be used to elucidate 
drug-drug interactions and for the identification of enzyme polymorphism (Court, 2005). 
However, the design of isoform-selective inhibitors for UGTs is difficult because these 
enzymes display overlapping substrate-selectivities and only a small number of selective 
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substrates for some UGT isoforms have been described (Court, 2005). This lack of specificity 
prevents the derivation of pharmacophores for the design of isoform-selective lead 
structures. In addition, UGT enzymes display in general low affinities toward their substrates, 
which renders it difficult to identify structural features that promote high affinity (Williams 
2005; Court, 2005). Yet another major obstacle is that most common functional groups in 
organic compounds that promote water solubility such as hydroxy, amino, thiol, and carboxy 
groups serve as nucleophiles in the enzymatic glucuronidation reaction. Hence, the 
incorporation of such groups bears the risk that the designed inhibitor turns out to be a 
substrate. The development of potent inhibitors is also challenging because the full-length 
crystal structure of any of the UGT isoforms is yet to be resolved. 
 
2. Review of the literature 
2.1 UDP-glucuronosyltransferases 
The UGTs are important enzymes of the phase II metabolic system. The metabolic phase II 
pathways comprise conjugation reactions mediated by enzymes such as UGTs, N-
acetyltransferases, sulfotransferases and glutathione S-transferases. The UGT enzymes 
catalyze the transfer of α-D-glucuronic acid (GlcA) from UDP-glucuronic acid (UDPGlcA) to 
lipophilic substrates bearing hydroxy, thiol, amino, sulfonamide, or carboxy groups, and even 
enolate moieties affording exclusively their corresponding O-, N-, S- and C-β-D-glucuronides 
(Figure 1). This conjugation reaction renders lipophilic endobiotics and xenobiotics more 
water soluble and stimulates their urinary and biliary excretion, thus preventing their 
accumulation to harmful levels (Wells, 2004; Fisher, 2001). It is assumed that all classes of 
drugs are substrates of UGTs and this pathway has been estimated to account for 
approximately 35% of all drugs metabolized by phase II drug metabolizing enzymes (DMEs; 
Evans, 1999). Furthermore, UGT enzymes contribute to the protection against toxic dietary 
components, tobacco smoke carcinogens, and environmental pollutants and they control the 
excretion of bilirubin, steroid and thyroid hormones, fatty and biliary acids (Guillemette, 
2003). Certain UGT isoforms may play also an important role as a protective barrier against 
genotoxic substances because the UGTs 1A6 and 2B7 are also present in the inner and 
outer nuclear membranes of human liver (Radominska-Pandya, 2005). 
 
Although the liver is the major site of metabolic pathways including glucuronidation, 
UGTs are also found in other tissues, for example, in the brain, prostate, uterus, breast, 
placenta, and kidney. These enzymes are also localized at the entry ports of foreign 
chemicals such as in the epithelial surfaces of the nasal mucosa, the gut, skin and lung, 
indicating their key role as host defense against toxic xenobiotics (Tukey and Strassburg, 
2000). 
 
The UGTs belong to the UDP-glycosyltransferase gene superfamily comprising four 
enzyme families, UGT1, UGT2, UGT3 and UGT8 (Mackenzie, 2005; Owens, 2005). The 
enzymes of the UGT1 and UGT2 families are using predominantly UDPGlcA as the 
cosubstrate. However, the UGT1 and UGT2 members may also use UDP-glucose and UDP-
xylose as a glycosyl donor. The gene of each member of the UGT superfamily is given the 
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root symbol UGT, “[…] followed by an Arabic number representing the family, a letter to 
denote the subfamily, and an Arabic number for the individual gene.” (Mackenzie, 2005, 
page 677) To date, 28 genes belonging to subfamilies UGT1A, UGT2A and UGT2B have 
been identified, nine of which contain mutations and are designated as pseudogenes 
(Mackenzie, 2005). 
 
All isoforms of the UGT1 family are encoded by a gene on chromosome 2q37 comprising 
approximately 200 kb. The four downstream exons (2-5) encode the C-terminal half of the 
protein. The 13 individual first exons (1A1-1A13P) encode the N-terminal half of the 
individual UGT isoforms. The mRNA encoding each isoform is generated by differential 
splicing and fusion of one of the upstream exons to the four downstream exons. This 
mechanism leads to UGT1 isoforms with different N-terminal domains, but identical C-
terminal halfs. Exons 2, 11, 12 and 13 are pseudogenes that contain non-sense mutations, 
namely stop codons (Owens, 2005). 
 
The mRNAs of the UGT2 family are transcribed from individual genes comprising six 
exons. The UGT2 family is further divided into the subfamilies UGT2A and UGT2B according 
to their primary amino acid sequence. The sequence of UGT2A members is <70% similar to 
that of UGT2B isoforms. The human UGT2 gene family appears to be tightly clustered on 
chromosome 4q13. Due to the transcription of the UGT2B mRNAs from individual genes, the 
C-terminal domains of the various UGT2B-subfamily members are not identical. However, 
isoforms of the UGT2B subfamily demonstrate greater sequence homology in the C-terminal 
half of the protein compared to that of the N-terminus (Mackenzie, 2005). 
 
Recently, the crystal structure of the cofactor-binding domain of UGT2B7 (2B7CT) was 
resolved by Miley and coworkers (Miley, 2007). The 2B7CT structure was found to be a 
globular domain with a Rossman-type fold. The core comprises a single β-sheet consisting of 
six individual strands and seven α-helices. Superposition of 2B7CT with GT1 plant flavonoid 
glucosyltransferase (VvGT1) revealed a high level of structural homology. These findings 
suggest that the UDPGlcA binding site may resemble the UDP-glucose binding site of 
VvGT1 and mutational analysis yielded further insights into the stabilization of UDPGlcA 
within the binding domain of UGT2B. Trp356 and Gln359 presumably interact with the uracil 
base, Glu382 may hydrogen bond to the ribose 2‟-hydroxy group, Asn378 presumably 
interacts with the α-phosphate moiety, whereas His374 may interact with the β-phosphate 
group. Thr373 presumably interacts with the α-phosphate via a water or ion-mediated 
contact, Asp398 and Gln399 are predicted to hydrogen bond to the glucuronic acid moiety 
and Asn378 may bond to the carboxy group of UDPGlcA. The structure of VvGT1 was used 
to generate a homology model of UGT2B7 to gain further insights into the catalytic 
mechanism. This model suggests that the UGT2B7-catalyzed conjugation reaction may 
resemble a serine protease- or endopeptidase-like catalytic triad. In this respect, His35 of 
UGT2B7 seems to act as the catalytic base responsible for deprotonating the nucleophilic 
group of the aglycone. The resulting protonated His35 residue may be stabilized by Asp151 
(Figure 1). These findings have been recently confirmed by Patana and coworkers, who 
revealed by conducting activity determinations, kinetic analyses and homology modeling that 
the amino acid residues His371 and Glu379 of UGT1A6 are presumably directly involved in 
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cofactor binding (Patana, 2007). Despite these seminal findings that represent the starting 
point in understanding the molecular mechanism underlying the UGT-catalyzed 
glucuronidation, the full-length crystal structure of any UGT has not been resolved to date 
and the detailed reaction mechanism of the enzymatic glucuronidation reaction remains 
therefore to be deciphered. In this respect, it remains unclear for UGT2B enzymes, whether 
the binding of substrate and cofactor to their respective binding domains follows a 
compulsory ordered or random mechanism. Recent findings suggest that UGT1A isoforms 
display a compulsory ordered mechanism in which UDPGlcA is presumably the first binding 
substrate (Luukkanen, 2005). 
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Figure 1. UGT-catalyzed glucuronidation of 1-naphthol. The enzymatic glucuronidation is assumed to resemble 
the bimolecular nucleophilic substitution reaction (SN2) affording exclusively β-D-glucuronides (according to Miley, 
2007). The release of OUDP may be facilitated by the presence of Mg
2+
 ions (Radominska-Pandya, 2005). 
 
 
Data indicate that at least some, if not all UGT enzymes form quaternary structures, such 
as homo- and heterodimers or even tetramers, also referred to as homo- or 
heterooligomerization. It has been assumed that UGTs may even be closely associated with 
other membrane-bound DMEs, such as cytochrome P450 enzymes and epoxide hydrolase 
presumably resulting in efficient biotransformation (Radominska-Pandya, 2005). Intriguing 
results have been reported by Ishii and coworkers showing that simultaneous expression 
(coexpression) of the UGTs 2B21 and 2B22 resulted in extensive glucuronidation of the 6-
hydroxy group of morphine (1). This finding is remarkable when taking into account that 
UGT2B21 did only provide very low amounts of morphine-6-glucuronide and UGT2B22 did 
not show any activity in the presence of morphine (Ishii, 2001). It has been therefore 
suggested that the formation of heterooligomers may result in altered substrate selectivities 
of UGT isoforms. A recent study performed by Kurkela and coworkers revealed that 
coinfection with UGT1A4 increased scopoletin glucuronidation of the Tyr485Asp mutant of 
UGT1A6 and that coinfection with most other human UGTs increased serotonin 
glucuronidation of this mutant. The results of this study indicated that such 
heterooligomerization might attenuate the effects of at least some pathological mutations in 
the UGTs (Kurkela, 2007). Furthermore, it has been shown that phosphorylation of UGTs 
may regulate their substrate selectivities. In this respect, a study conducted by Basu and 
coworkers revealed that phosphorylation of Ser432 of UGT1A7 altered the substrate 
selection of this isoform (Basu, 2005). 
 
The compartmentation theory suggests that the catalytic domain of the UGT enzymes is 
located on the luminal surface of the endoplasmic reticulum (ER; Figure 2). This assumption 
is supported by experimental evidence showing that intact microsomal preparations, „right-
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side-out‟ closed vesicles from liver cells, display enzyme latency; i.e., the membrane has to 
be disrupted by chemical or physical means to achieve full glucuronidation potential. It has 
been reported that sonication, cycles of freezing and thawing, poreforming agents, and 
detergents increase enzyme activity. The removal of UGT latency, for example in the 
presence of the membrane-disrupting agent alamethicin is probably due to the increased 
access of substrate and cosubstrate to the luminal site of the ER (Radominska-Pandya, 
2005). 
 
 
 
 
Figure 2. Presumed mechanism of the UGT-catalyzed glucuronidation. (1) Translocation 
of aglycone and UDPGlcA from the cytosol to the ER lumen. (2) Binding of the aglycone 
and UDPGlcA to their corresponding binding domains. (3) Formation of the transition 
state and transfer of GlcA from UDPGlcA to the aglycone. (4) Release of β-D-glucuronide 
and UDP. (5) Translocation of β-D-glucuronide and UDP to the cytosol. 
 
 
Seven UGT isoforms of the UGT1 and UGT2 families are assumed to play major roles in 
drug metabolism (Burchell, 2005). UGT2B7 is presumably the key enzyme involved in drug 
glucuronidation whose activity may account for the transformation of 40% of drugs that are 
metabolized by UGT isoforms (Burchell, 2005; Williams, 2004). The UGTs 1A1, 1A4, and 
1A9 are assumed to be equally responsible for a further 47% of drug glucuronidation in the 
liver. UGTs are promiscuous enzymes that are commonly described to possess a high 
degree of flexibility to depict their complex and often overlapping substrate selectivities 
(Meech, 1997). This feature is assumed to be a defining property of metabolic enzymes such 
as UGTs, cytochrome P450s, and glutathione S-transferases. These enzymes apparently 
evolved to possess broad substrate selectivities so that they can detoxify a wide range of 
harmful compounds and represent therefore an effective protective barrier against xenobiotic 
exposure (Copley, 2003). This flexibility comes at the cost of potency, a defining 
characteristic of promiscuous enzymes, because typical Km values of UGT substrates are in 
the micromolar range (Williams, 2005; Miley, 2007). Many substrates exhibit atypical kinetic 
behavior that may be interpreted as involving multiple substrate binding sites. Furthermore, 
UGTs may generate multiple metabolites from a single substrate that bears more than one 
nucleophilic group, indicating multiple binding modes within the aglycone-binding domain of 
the UGT enzyme (Miners, 2004). For example, UGT2B7 catalyzes both the 3-hydroxy and 6-
hydroxy glucuronidation of morphine (1), strongly indicating that this substrate adopts at least 
two distinct spatial orientations within the substrate-binding domain (Wittwer, 2006). 
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To date, only a few selective substrates for some hepatic UGTs have been described, 
presumably due to the promiscuous character of DMEs (vide supra). These selective 
substrates comprise bilirubin (2), HMR1098 (3), the 3-hydroxy group of estradiol (4), and 
17α-ethinylestradiol (5) for UGT1A1; 2-aminobiphenyl (6), trifluoperazine (7) and amitriptyline 
(8) for UGT1A4; 1-naphthol (9) and serotonin (10) for UGT1A6; propofol (11) and tolcapone 
(12) for UGT1A9; the 6-hydroxy group of morphine (1), hyodeoxycholic acid (13), AZT (14), 
carbamazepine (15) and farnesol (16) for UGT2B7; and (S)-oxazepam (17) for UGT2B15 
(Burchell, 2005; Court, 2005). In this respect it should be mentioned that although UGT1A6 
presumably displays the highest activity for 1-naphthol, this substrate is also glucuronidated 
by many other UGT isoforms. Furthermore, the 3-hydroxy group of estradiol is 
glucuronidated faster by the extrahepatic UGT1A10 than by the hepatic UGT1A1 and 
hyodeoxycholic acid has been reported to be also glucuronidated by UGT2B4 (Barre, 2007). 
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2.2 Clinical aspects of enzymatic glucuronidation 
The clinical response of therapeutic drugs depends frequently on genetic factors such as 
polymorphisms, insertions and deletions, or single-nucleotide polymorphisms (SNPs; Evans, 
1999). These genetic factors may significantly alter the function and/ or expression of a 
protein, thereby leading to significant alterations in the pharmacological and toxicological 
profiles of drugs. In recent years, however, it has been recognized that alterations in genes 
encoding for UGTs may increase, decrease or even abolish their activities toward drugs and 
carcinogens resulting in the exposure to these compounds over a long period of time, which 
may increase the risk for drug-induced toxicity and development of cancer. However, only a 
few clinically relevant polymorphisms for UGT enzymes have been described (Guillemette, 
2003). Furthermore, genetic alterations in the coding and promoter region of UGT1A1 are of 
significant clinical importance due to the development of inherited hyperbilirubinemias 
(Bosma, 2003). 
 
Unconjugated hyperbilirubinemia. UGT1A1 is the key enzyme involved in the 
glucuronidation of bilirubin (2), a toxic breakdown product of heme. Unconjugated 
hyperbilirubinemias include the Crigler-Najjar syndrome types I and II (CN-I and CN-II, 
respectively) and Gilbert‟s syndrome. Patients with CN-I and CN-II display serum bilirubin 
levels of 30-50 mg/dL and 6-20 mg/dL, respectively. CN-I is a severe disorder and patients 
did not reach adulthood before the discovery of phototherapy and the development of liver 
transplantations. In contrast, patients with the benign Gilbert‟s syndrome do not require 
treatment, because the serum bilirubin level of patients with Gilbert‟s syndrome reaches only 
5 mg/mL. The severe forms of the unconjugated hyperbilirubinemias, CN-I and CN-II, result 
from numerous distinct mutations in the UGT1A1 gene (point mutations, deletions and 
insertions). In contrast, the mild form of the unconjugated hyperbilirubinemia, Gilbert‟s 
syndrome, stems predominantly from a mutation in the TATA-box region of the UGT1A1 
promoter, but also other mutations may cause this form of mild hyperbilirubinemia. The 
dominant variant allele responsible for Gilbert‟s syndrome displays an A(TA)7TAA region 
(UGT1A*28), whereas the wild-type allele is characterized by A(TA)6TAA (UGT1A1*1) in the 
promoter region. A(TA)7TAA results in a decreased transcription initiation of the UGT1A1 
gene compared to A(TA)6TAA (Bosma, 2003). 
 
Cancer. Certain polymorphisms in UGT genes have been linked to the risk for some 
cancers, presumably owing to an impaired ability of the respective enzyme to inactivate 
exogenous mutagenic compounds. UGT enzymes are also involved in the control of 
hormonal signal cascades, by catalyzing the conjugation of steroid hormones to GlcA, which 
results predominantly in the termination of endocrinological activity. Polymorphisms in UGT 
genes leading to impaired steroid-hormone glucuronidation are therefore assumed to 
contribute to the risk of cancer because tumor growth of some cancers is controlled by 
steroid hormones. UGT1A7 plays a key role in the glucuronidation of carcinogenic 
metabolites of tobacco-specific nitrosamines and benzo[a]pyrene. The enzyme is expressed 
in the aerodigestive tract including the larynx and other tissues. A study conducted by Zheng 
and coworkers revealed that the low-activity alleles UGT1A7*3 and UGT1A7*4 were 
positively associated with orolaryngeal cancer (Zheng, 2001). For the estrogen-conjugating 
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UGT isoform 1A1, however, conflicting data concerning the link between low-activity alleles 
of UGT1A1 and breast cancer have been reported (Guillemette, 2003). UGT2B7, which plays 
a key role in the metabolism of androgens, estrogens, pregnanes, bile acids and retinoic 
acids, has been proposed to exert an anti-neoplastic function for breast cancer due to the 
observations that the enzyme is expressed in the epithelium lining the mammary ductal 
system and that the glucuronidation rate of estrogen is significantly lower in neoplastic 
tissues compared to normal tissues (Gestl, 2002). 
 
Irinotecan. Irinotecan (Camptosar) is a topoisomerase I inhibitor used in the treatment of 
metastatic colorectal cancer and small-cell lung cancer. It is a pro-drug, which is hydrolyzed 
to its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) by carboxylesterases (CES) 
in man (Figure 3). Hepatic and extra-hepatic glucuronidation represents the major pathway 
for SN-38 inactivation and the formed SN-38 glucuronide (SN-38G) is eliminated in bile. The 
key enzyme responsible for SN-38 glucuronidation is presumably UGT1A1, whereas it is 
assumed that UGT1A9 and UGT1A7 play only minor roles. SN-38 can cause severe, therapy 
limiting diarrhea and neutropenia associated with great interpatient variability. 
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Figure 3. Enzymatic hydrolysis of irinotecan by CES affords its corresponding active metabolite SN-38. The key 
metabolic pathway is presumably the UGT1A1-catalyzed conjugation yielding SN-38G. 
 
 
Impaired glucuronidation activity of UGT1A1 has been reported to be associated with 
elevated levels of SN-38, which might cause toxicity during therapy. Mainly the variant 
UGT1A1*28 results presumably in higher concentrations of active SN-38, which have been 
found to be associated with a greater risk of neutropenia in cancer patients. This finding 
prompted the US Food and Drug Administration (FDA) to change the label of irinotecan, 
which now includes a warning of greater risk of neutropenia in patients with decreased 
glucuronidation activity. The FDA recommends a decrease in dose administered to 
UGT1A1*28 homozygous patients, although the effect of this dose reduction on therapeutic 
efficacy remains unclear. Furthermore, the FDA approved an in vitro diagnostic test for 
detecting the wild type (UGT1A1*1) and UGT1A1*28 variant; however, the UGT1A1*28 
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genotyping test is not mandatory before starting the irinotecan regimen (Hahn, 2006; Kim 
and Innocenti, 2007). 
 
Drug-drug interactions. Garnett and coworkers reported that coadministration of 
lamotrigine (18) with valproic acid (19) presumably elevates the risk of rash. However, it has 
been also revealed that the concomitant administration of lamotrigine with valproic acid 
results in increased anticonvulsive efficacy (Garnett, 2002). The coadministration of the 
NSAID zomepirac (20) with probenecid (21) results in a significant increase in plasma 
concentration of zomepirac (20), which may be only partly due to inhibition of UGTs (Smith, 
1985). Despite these findings, evidence for clinically relevant pharmacokinetic and 
pharmacodynamic events resulting from drug-drug interactions in UGT enzymes is rare, 
presumably stemming predominantly from the involvement of multiple different DMEs in the 
metabolism of UGT substrates and their low affinities toward UGTs resulting in low exposure 
ratios, also referred to as AUCi/AUC (Williams, 2004). 
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Acyl glucuronides. The UGT isoforms 1A3, 1A9 and 2B7 play major roles in the 
glucuronidation of carboxy groups of endogenous and exogenous compounds such as 
bilirubin (2), all-trans retinoic acid (22), nonsteroidal anti-inflammatory drugs (NSAIDs) like 
diflunisal (23), zomepirac (20), benoxaprofen (24), tiaprofenic acid (25), fenoprofen (26), 
ibuprofen (27), ketoprofen (28), naproxen (29), fibrate hypolipidaemic agents like clofibric 
acid (30) and gemfibrozil (31), the diuretic agent furosemide (32), and the anticonvulsant 
valproic acid (19). The corresponding acyl glucuronides are reactive compounds due to their 
electrophilic acetal ester group, which can undergo acyl shift reactions at the GlcA moiety. 
The acyl glucuronides are susceptible to react with nucleophilic groups of proteins, such as 
the lysine ε-amino group, via the glycation and/ or transacylation pathway leading to the 
formation of structurally and functionally altered protein adducts (Sallustio, 2000). These 
protein adducts are presumably involved in the occurrence of hepatotoxic and anaphylactic 
events. Dipeptidyl peptidase IV and tubulin have been identified to be covalently modified by 
zomepirac (20) acyl glucuronide (Wang, 2001; Bailey, 1998). Furthermore, a recent study 
has revealed that rapid glucuronidators of diclofenac are at greater risk to develop 
diclofenac-induced hepatotoxicity compared to normal glucuronidators, presumably due to 
the resulting high concentrations of the acyl glucuronide within hepatocytes of rapid 
glucuronidators (Daly, 2007). 
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Bioactivation. The traditional picture of UGT enzymes is that of deactivating and 
detoxifying DMEs. However, some endogenous and xenobiotic compounds are bioactivated 
by enzymatic glucuronidation yielding glucuronides that display higher pharmacological and/ 
or toxicological activity compared to their unconjugated, parent aglycone (cf. also acyl 
glucuronide formation). Recently, a study performed by Sakamoto and coworkers showed 
that administration of the glucuronide of S-8921 (33), a novel inhibitor of the ileal apical 
sodium-dependent bile acid transporter (ASBT), resulted in significantly reduced serum 
concentration of non-high density lipoprotein (non-HDL) cholesterol in rats, whereas the 
unconjugated S-8921 (33) did not exert a detectable effect on the non-HDL concentration in 
Gunn rats, which are devoid of UGT1A activity (Sakamoto, 2007). Furthermore, the S-8921 
glucuronide (Ki = 18 nM) was 6000-fold more potent in its inhibitory activity of ASBT in vitro 
compared to its unconjugated form (Ki = 109 µM). The opioid analgesic morphine (1) is 
metabolized in vivo to morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), 
the latter displaying a two to four times greater pharmacological activity compared to 
unconjugated morphine, whereas M3G is virtually devoid of any activity toward opioid 
receptors. It is assumed that M6G exerts less undesired side effects such as respiratory 
depression, nausea and vomiting compared to morphine (Kilpatrick, 2005; Wittwer, 2006). 
Bioactivation mediated by UGT-catalyzed glucuronidation has also been reported for the 
active metabolites of vitamin A, all-trans retinoic acid (22) and all-trans retinol (34), and for 
the estrogens estriol (35), 17β-estradiol (4), and 17α-ethinylestradiol (5) (Ritter, 2000). 
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Repeated glucuronidation. Murai and coworkers have recently shown that incubation of 
estrone (36) and testosterone (37) with human liver microsomes resulted not only in the 
formation of their corresponding monoglucuronides, but also in the formation of their 
diglucuronide metabolites estrone 3-O-diglucuronide and testosterone 17-O-diglucuronide. 
The diglucuronides were not further metabolized to triglucuronides at detectable rates 
indicating that the diglucuronides were not further recognized as UGT substrates (Murai, 
2005). The results of this in vitro study revealed that the diglucuronide metabolites were only 
formed in very low amounts and, hence, there may be no physiological or clinical significance 
associated with this diglucuronidation pathway in vivo. 
 
2.3 UDP-glucuronosyltransferase 2B7 
The UGT2B7 enzyme exists in two variants, referred to as UGT2B7(H) and UGT2B7(Y), 
depending on whether a histidine (H) or tyrosine (Y) residue is located at position 268 of the 
corresponding primary amino acid sequence, respectively. This difference is presumably not 
associated with distinct substrate selectivities, even though varying activities toward their 
common substrates have been reported (Coffman, 1997). The crystal structure of the C-
terminus of UGT2B7 (2B7CT) has been recently reported; however, the full-length crystal 
structure still remains to be resolved (Miley, 2007; vide supra). 
 
UGT2B7 is localized in the liver but also in extrahepatic tissues of the human body such 
as the kidney, gastrointestinal (GI) tract, small intestine, colon, esophagus, brain, pancreas 
and mammary gland. Since the GI tract represents the first large organ encountered by orally 
administered drugs, it seems likely that UGT2B7 may be involved in the first-pass 
metabolism of drugs. UGT2B7, like all other UGT isoforms, resides in the ER. However, the 
2B7 isoform is also present in the nuclear membrane of human liver and intestine, 
suggesting that UGT2B7 is involved in defense mechanisms to protect the nucleus from 
mutagenic compounds (Chouinard, 2004). Furthermore, this isoform plays a key role in the 
glucuronidation of steroid hormones presumably to regulate the level of these nuclear 
receptor ligands and their endocrinological activity (Radominska-Pandya, 2001; Bélanger, 
2003). 
 
UGT2B7 displays broad substrate selectivity and conjugates structurally distinct 
endogenous compounds, such as fatty acids, bile acids, retinoids and steroid hormones, and 
drugs such as the opioid analgesics morphine (1) and buprenorphine (38), the NSAIDs 
acetaminophen (39), diclofenac (40) and ketoprofen (28), the HIV-reverse transcriptase 
inhibitor AZT (14) and the β1 adrenergic agonist dobutamine (41). Interestingly, also 
UGT2B7-catalyzed amide N-glucuronidation has been reported for the maxi-K channel 
opener BMS-204352 (42) (Zhang, 2004), despite a generally observed preference for 
hydroxy and carboxy groups. Although UGT2B7 displays broad substrate selectivity, the 
results of inhibition and NMR studies suggested that UGT2B7 contains only one substrate-
binding domain in contrast to UGT1A1, the latter providing at least two distinct binding sites, 
one for buprenorphine (38) and the other for bilirubin (2) (Coffman, 2001; Rios, 2002). 
 
UGT2B7 is presumably the key enzyme involved in the formation of acyl glucuronides, 
and, as a consequence, it may be involved in the onset of adverse reactions like 
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hepatotoxicity after administration of carboxy group containing NSAIDs like diclofenac (40) 
and zomepirac (20) (vide supra). UGT2B7 is also responsible for the detoxification of 
carcinogens such as polycyclic aromatic hydrocarbons, e.g., hydroxylated benzo[a]pyrenes, 
and it has been reported that the enzyme is downregulated and exerts low activity in 
endometrial cancer and advanced ovarian cancer, suggesting that its reduced activity may 
be involved in carcinogenesis (Radominska-Pandya, 2001). 
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2.4 UDP-glucuronosyltransferase 2B17 
Expression of UGT2B17 mRNA has been found in various tissues including the liver, kidney, 
testis, uterus, placenta, mammary gland, adrenal gland, skin, and prostate (Beaulieu, 1996). 
UGT2B17 is assumed to be a key enzyme involved in the inactivation of androgens, such as 
dihydrotestosterone (43, DHT) and its metabolites androsterone (44, ADT) and androstane-
3α,17β-diol (45, 3α-DIOL), in steroid-sensitive tissues (Bélanger, 2003). The UGTs 2B17 and 
2B15 are 95% identical in primary structure. Despite this high identity, UGT2B17 conjugates 
the 3α- as well as the 17β-hydroxy group of C19 steroids (androgens), whereas 2B15 
presumably recognizes exclusively the 17β-hydroxy group (Beaulieu, 1996; Turgeon, 2003) 
indicating that small changes in primary structure may result in significant altered substrate 
selectivity and/ or regioselectivity. Indeed, Dubois and coworkers showed that the exchange 
of serine at position 121 with tyrosine abolished the activity of UGT2B17 for the 3α-hydroxy 
group of ADT (44), whereas the enzyme retained activity for the 17β-hydroxy group of DHT 
(43) (Dubois, 1999). Therefore, this single amino acid exchange resulted in higher 
regioselectivity of the enzyme. This notion that promiscuous enzymes may acquire higher 
selectivity and/ or activity resulting from small amino acid changes (plasticity) has been 
recently discussed with respect to the molecular evolution of more specific and active 
enzyme functions. In this respect, it is believed that enzymes with high selectivity and/ or 
activity evolved from promiscuous precursor enzymes by a process known as divergent 
evolution (gene duplications and subsequent mutations). The significant alteration in 
substrate selectivity and/ or activity by a small number of amino acid substitutions 
presumably allows the organism to adapt rapidly in response to environmental changes 
(Yoshikuni, 2006). 
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A distinct cellular distribution of the highly homologous UGT isoforms 2B17 and 2B15 has 
been found in the androgen-sensitive prostate (Chouinard, 2004). In this respect, the 
expression of UGT2B17 is limited to the basal cells of the prostate, whereas UGT2B15 is 
detected exclusively in the luminal cells. It has been also revealed that UGT2B17 is 
predominantly involved in the conjugation of the testosterone metabolites 3α-DIOL (45) and 
ADT (44), whereas UGT2B15 displays high activity for DHT (43), the latter exerting an 
approximately 5-10 times higher affinity to the androgen receptor than its precursor 
testosterone (37). Further analysis revealed that 3α-DIOL (45) and ADT (44) are presumably 
exclusively produced in the basal cells, whereas high concentrations of DHT (43) have been 
found in the luminal cells of the prostate. These findings indicated that the UGTs 2B17 and 
2B15 play complementary roles in androgen metabolism and are expressed in cells, where 
their specific substrates are synthesized (Bélanger, 2003). These results suggest that these 
isoforms play an important role in regulating androgen levels in androgen-sensitive tissue 
and in terminating androgenic activity at the site of their synthesis. Since androgens 
stimulate prostate cancer cells, it might be suggested that low-activity alleles of androgen 
conjugating enzymes could increase the risk of prostate cancer. Indeed, it has been shown 
that slow glucuronidators of DHT (43), which are homozygous for the low activity-allele 
2B15*D85, are at greater risk to develop prostate cancer than normal glucuronidators 
(Bélanger, 2003).  
 
To date, UGT2B17 has been mainly studied for its ability to conjugate steroid hormones, 
and its involvement in the metabolism of xenobiotics remains to be elucidated in detail. Two 
studies revealed that UGT2B17 is not exclusively active on androgens, but conjugates also 
C18 (estrogens) and C21 (gestagens) steroids as well as exogenous compounds such as 
coumarins, NSAIDs, anthraquinones, flavonoids, monoterpenols, and phenolic compounds. 
However, 2B17 does presumably not glucuronidate opioid analgesics, such as morphine (1), 
which is believed to be a selective substrate of UGT2B7 (Bélanger, 1998, Turgeon, 2003). 
 
2.5 Stereochemical aspects of enzymatic glucuronidation 
The interactions between chiral compounds and functional proteins have long been known to 
be stereoselective and it has become evident that both pharmacodynamic and 
pharmacokinetic processes contribute to the overall observed stereoselectivity (Crossley, 
1995; Eichelbaum et al., 2003). It has been further recognized that the use of optically pure 
drugs should be advantageous, as this should reduce the total dose given, minimize toxicity, 
simplify the dose-response relationship, and also remove a source of intersubject variability 
(Ariëns, 1984; Caldwell, 2001). This understanding has led to an increased preference for 
optically pure compounds, and as a result, single-enantiomer drugs represent today the 
leading category of Food and Drug Administration (FDA) approved entities (Agranat et al., 
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2002). In addition, the strategy of chiral switches serves as a second source for single-
enantiomer drugs entering the market. Chiral switches are chiral drugs that have already 
been marketed as mixtures of stereoisomers, but have since been redeveloped as single 
enantiomers (Agranat et al., 2002; Tucker, 2000). 
 
The ability of a probe to distinguish between enantiomers of a chiral compound is 
referred to as chiral discrimination or chiral distinction. In drug design and development, 
these probes are usually homochiral, functional proteins of the cell, such as enzymes, 
receptors, ion channels and transporters, which are built up (almost) exclusively of L-amino 
acids (homochirality). 
 
The requirements for chiral recognition may be summarized as follows. (1) The binding of 
two enantiomers of a chiral compound (-A) and (+A) to the homochiral protein (-P) results in 
two possible combinations (-A)(-P) and (+A)(-P). These complexes display a diastereomeric 
relationship, i.e., they possess distinct physicochemical properties. This concept is also 
referred to as diastereomeric discrimination. (2) The concept of chiral distinction implies also 
that the enantiomers of a chiral compound display distinct interactions to crucial amino acid 
residues within a given binding domain of a protein, resulting in different potencies and/ or 
efficacies. A minimum of four contact points between the enantiomer and the protein, either 
repulsive or attractive, are required. The contact points comprise four different, nonplanar 
centers on each molecule. This concept is also referred to as the four-contact point model. In 
general, both models contribute to the overall observed chiral distinction (Bentley, 2003). 
 
However, it has been noticed that these models are somehow too simplistic and cannot 
fully account for the observed high levels of chiral distinction displayed by functional proteins 
that allow the enantiomers of a chiral compound to fit into the binding domain in alternate 
ways (Bentley, 2003). This scenario is getting even more complicated when the enantiomers 
of a chiral compound display a high degree of flexibility due to rotational freedom along σ-
bonds. For example, it has been found that the flexible enantiomeric substrates (R)-MPP-C7 
(46) and (S)-MPP-C7 (47) adopt surprisingly similar spatial orientations within the active site 
of Burkholderia cepacia lipase (Mezzetti, 2005). In this respect, three of the four substituents 
at the stereocenter of the enantiomers lie in similar spatial positions (mirror-image packing). 
These subtle differences in their spatial orientations resulted in a surprisingly high level of 
chiral distinction during the lipase-catalyzed ester hydrolysis (kcat ratio = 1000), whereas the 
affinity of the two enantiomers to the binding domain of the lipase was almost identical (Km 
ratio = 0.75). 
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Eudismic analysis relates to the study of stereoselective events resulting from the 
interactions between chiral molecules and the homochiral constituents of the body. In the 
case of enzyme-catalyzed reactions, the enantiomeric substrates may be metabolized at 
different rates (different efficacies) or may display distinct affinities to the binding domain 
(different potencies). The more active enantiomer is called eutomer, its corresponding less 
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active stereoisomer is termed distomer. The initial finding that the logarithm of the ratio of the 
potencies or efficacies of enantiomers for a number of drugs was proportional to the 
logarithm of the administered dose was the starting point for eudismic analysis in 
pharmacology and related disciplines (Pfeiffer, 1956). The ratio between the potencies or 
efficacies is called the eudismic ratio or stereospecific ratio, and its logarithm is referred to as 
eudismic index or stereospecific index. Pfeiffer‟s rule states that the eudismic index should 
increase linearly with increasing efficacy or potency of the eutomer (Crossley, 1995). A plot 
of the eudismic index against the logarithm of the potency or efficacy of the eutomer should 
give a straight line. The slope of this straight line is termed eudismic activity quotient. Such 
correlation indicates a significant involvement of the stereocenter during the binding or 
tranformation process, whereas a lack of correlation points to no significant involvement of 
the element of chirality. However, lack of correlation may be also due to other factors such as 
the existence of two or more binding domains and unspecific, noncompetitive or 
uncompetitive binding to the enzyme. It has been also shown that the purity of the 
enantiomeric probe substrates (enantiomeric resolution) is crucial for the observed eudismic 
ratios. In this respect, the measured eudismic ratio is highly dependent on the degree of 
resolution (Barlow, 1971 and 1972). One limitation of the eudismic ratio is that it is not linked 
to structural and physicochemical properties of the chiral molecules (Barlow, 1990). Attempts 
have been undertaken to link observed eudismic ratios to properties of chiral entities such as 
chirality coefficients, free energy-related parameters and chiral topological indices in order to 
overcome this limitation (Lien, 1975; Levy and Richards, 1993; Levy, 1994; Julián-Ortiz, 
1998). 
 
As discussed previously, promiscuous UGTs display in general high flexibility allowing 
substrate molecules to fit into their corresponding binding domains in different spatial 
orientations. UGTs are therefore generally not considered to display high levels of chiral 
distinction (Crossley, 1995). This could be the reason these enzymes are generally not 
subjected to eudismic analysis using whole series of chiral compounds. However, some 
chiral drugs have been investigated for their stereoselective conjugation by UGT enzymes, 
and the results are summarized here below. 
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Flurbiprofen (48). A recent study performed by Mano and coworkers revealed that the 
(R)- and (S)-enantiomer of the NSAID flurbiprofen (48) were conjugated predominantly by 
UGT2B7. The glucuronidation rate for (R)-flurbiprofen was 2.8-fold higher than that for its 
mirror-image compound, and the Km values of the (R)- and (S)-enantiomer were 12 and 7.5 
µM, respectively (Mano, 2007). In an earlier study using rat liver microsomes, Hamdoune et 
al. showed that (R)-flurbiprofen was glucuronidated at a higher rate than its (S)-enantiomer 
(9.3 and 5.5 nmol/min mg protein, respectively), whereas their corresponding Km values were 
almost identical (0.52 and 0.57 mM, respectively; Hamdoune, 1994). 
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Oxazepam (17). The anxiolytic drug oxazepam (17) is formulated as a racemic mixture, 
and UGT-catalyzed glucuronidation represents its predominant metabolic pathway. Using the 
racemic mixture, (S)-oxazepam has been found to be a highly selective substrate for 
UGT2B15, whereas its corresponding (R)-stereoisomer was glucuronidated mainly by 
UGT1A9 and 2B7 (Court, 2002). Although UGT2B7 glucuronidated (S)-oxazepam at very low 
rates, this isoform conjugated preferentially its respective (R)-enantiomer (eudismic ratio 
(R)/(S) >5). In this study, even the Km values for both (R)- and (S)-enantiomers have been 
reported even though it was not determined, whether both enantiomers displayed affinity to 
the isoforms. Although this could be resolved by the use of purified enantiomers, both 
stereoisomers spontaneously racemize in aqueous solution at 37 °C (t½ ~ 4 min; Aso, 1988). 
 
Propranolol (49). In a recent study, Sten and coworkers revealed that UGT1A9 and 
UGT1A10 displayed opposite stereoselectivity in the glucuronidation of the β-adrenergic 
blocker propranolol (49) (Sten, 2006). UGT1A9 preferentially glucuronidated (S)-propranolol 
(eudismic ratio ~ 11), whereas UGT1A10 preferred the conjugation of its (R)-enantiomer 
(eudismic ratio ~ 4.2). Presumably due to the extrahepatic expression of UGT1A10 on the 
one hand and the hepatic expression of UGT1A9 on the other it has been also found that 
human liver microsomes glucuronidated predominantly (S)-propranolol, whereas human 
intestine microsomes glucuronidated its enantiomer at higher rates. The eudismic ratios for 
the microsomal preparations were not as large as those for the isolated human recombinant 
UGT1A9 and UGT1A10 enzymes, presumably due to the involvement of other UGT isoforms 
contributing to the overall clearance of the enantiomers of propranolol (49). 
 
Carprofen (50). A study conducted by Maire-Gauthier et al. revealed that liver 
microsomes prepared from different species, namely rat, dog, horse, sheep and man, display 
distinct stereoselective glucuronidation of the chiral NSAID carprofen (50) (Maire-Gauthier, 
1998). The liver microsomes of rat conjugated (R)-carprofen at much higher rates than its 
(S)-enantiomer (eudismic ratio ~ 4.8), whereas human liver microsomes displayed only a 
small preference for (R)-carprofen (eudismic ratio ~ 1.8). However, the Km values of the (R)- 
and (S)-enantiomer of carprofen (50) for all species were close to unity indicating similar 
affinities to the binding domain of the enzymes responsible for carprofen (50) 
glucuronidation. However, the purities of the (R)- and the (S)-enantiomer were only 98.2 and 
98.3%, respectively, hence, the apparent eudismic ratios could be underestimates of the true 
values (vide supra). 
 
Zileuton (51). It has been shown that the (S)-enantiomer of the chiral 5-lipoxygenase 
inhibitor zileuton (51) was selectively glucuronidated by dog liver microsomes, whereas its 
corresponding (R)-enantiomer was not conjugated (Sweeny and Nellans, 1991). 
Furthermore, this study revealed that the nonsubstrate (R)-zileuton caused an increase in the 
glucuronidation of the (S)-enantiomer presumably by increasing its affinity. A second study 
performed by Sweeny and Nellans investigated the stereoselective conjugation of zileuton 
(51) by human liver microsomes (Sweeny and Nellans, 1995). In contrast to their results for 
microsomal preparations from dog, human liver microsomes glucuronidated both 
enantiomers of zileuton (51). However, the (R)-enantiomer was glucuronidated at a faster 
rate compared to its (S)-stereoisomer (eudismic ratio ~ 3.4), whereas their affinities were 
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almost identical (eudismic ratio ~ 1.2). Furthermore, each enantiomer competitively inhibited 
the glucuronidation of its mirror-image compound. 
 
In summary, the above presented results reveal that eudismic ratios for the rates of 
stereoselective glucuronidation indicate low to moderate levels of chiral distinction for the 
UGT-catalyzed conjugation reaction. Furthermore, also the eudismic ratios for the affinities 
were close to unity. These results are in accordance with the general assumption that 
promiscuous DMEs do not display high levels of chiral distinction. Nevertheless, the 
investigation of stereoselective glucuronidation revealed that (S)-oxazepam was a highly 
selective substrate of UGT2B15. Furthermore, the study by Sten et al. showed that the 
tissues of the human body may contribute differently to the overall observed stereoselective 
glucuronidation. Interestingly, Sweeny and Nellans revealed that (R)-zileuton accelerated the 
glucuronidation of its enantiomer in one species (dog), whereas in another species (man) the 
same enantiomer, (R)-zileuton, inhibited the glucuronidation of its corresponding (S)-
enantiomer. 
 
2.6 Inhibitors of UDP-glucuronosyltransferases 
Isoform-selective and potent inhibitors for UGTs and other metabolic enzymes are 
valuable tools for biochemical studies. They facilitate the identification of enzymes that are 
responsible for drug metabolism and can be applied to testing in human tissue. Furthermore, 
selective inhibitors can be used to elucidate drug-drug interactions and for the identification 
of enzyme polymorphism (Court, 2005). They can be also applied to obtain better insight into 
the physiological and pathophysiological significance of metabolic pathways. 
 
However, the design of isoform-selective inhibitors for UGTs is difficult because these 
enzymes display overlapping substrate-selectivities and only a small number of selective 
substrates for some UGT isoforms have been described (vide supra). This lack of specificity 
prevents the derivation of pharmacophores for the design of isoform-selective lead 
structures. In addition, UGT enzymes display in general low affinities toward their substrates, 
which renders it difficult to identify structural features that promote high affinity (Williams 
2005; Court, 2005). Yet another major obstacle is that the most common functional groups in 
organic compounds that promote water solubility such as hydroxy, amino, thiol, and carboxy 
groups serve as nucleophiles in the enzymatic glucuronidation reaction. Hence, the 
incorporation of such groups bears the risk that the designed inhibitor turns out to be a 
substrate. The development of potent inhibitors is also challenging because the full-length 
crystal structure of any of the UGT isoforms is yet to be resolved. Furthermore, the possible 
involvement of multiple, structurally distinct substrate-binding domains of UGTs renders it 
difficult to design inhibitors that impair the glucuronidation of all substrates of a particular 
UGT isoform such as UGT1A1, which possesses at least two distinct binding sites (Rios, 
2002). 
 
Some inhibitors of UGT enzymes have been reported, but most of them lack desirable 
levels of isoform-selectivity and affinity (Grancharov, 2001). Although transition state (TS) 
analogues for UGTs were proposed (Timmers, 1997; Noort, 1991), they did not display the 
high potency that is generally associated with TS mimics (Schramm, 2005). These inhibitors 
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should therefore not be considered as meaningful representations of true TS mimics and 
could be better described as bisubstrate analogues. The lack of potency of these compounds 
is probably due to the shortfall to address TS-defining features such as bond-lengths, bond-
angles, and electrostatic potential surfaces. In general, true TS analogues are designed on 
the basis of kinetic isotope effects, computational approaches, and crystallographic analysis, 
none of which has been conducted for UGT enzymes to date. Therefore and despite various 
attempts, it has been proven relatively unsuccessful to pursue the design of inhibitors for 
UGT enzymes merely by attaching a UDP-like entity to a lipophilic moiety (Said, 1992; Noort, 
1990). Other attempts were driven by the screening of commercially available compounds 
and one screening approach led to the discovery of hecogenin (52) as a potentially isoform-
selective inhibitor of UGT1A4 (Uchaipichat, 2006). The results of inhibitor studies are 
summarized here below. 
 
Etonitazenyl isothiocyanate (53) and flunitrazepam (54). A study performed by Rios and 
Tephly revealed that the selective µ-opioid receptor antagonist etonitazenyl isothiocyanate 
(53) competitively inhibited the UGT2B7-catalyzed glucuronidation of morphine (1) and ADT 
(44) (Rios, 2002). The competitive inhibition constants (Kic) for etonitazenyl isothiocyanate 
(53) were 71 and 141 µM when assayed with morphine (1) and ADT (44), respectively. Also 
flunitrazepam (54), a nonsubstrate of UGT2B7, competitively inhibited the UGT-catalyzed 
glucuronidation of morphine (1) and losartan (55), displaying Kic values of 25 and 55 µM, 
respectively. However, etonitazenyl isothiocyanate (53) also inhibited the UGT1A1-catalyzed 
buprenorphine (38) conjugation (Kic = 5.5 µM) and, therefore, etonitazenyl isothiocyanate 
(53) was not a selective inhibitor. The isoform selectivity of flunitrazepam (54) was not 
determined. Interestingly, it was also revealed that neither etonitazenyl isothiocyanate (53) 
nor buprenorphine (38) displayed inhibition of the UGT1A1-catalyzed bilirubin (2), 2-
hydroxyestrone (56) and anthraflavic acid (57) glucuronidation and it was therefore 
suggested that UGT1A1 possessed at least two distinct substrate-binding domains. (Rios, 
2002). Previous to these findings, it had been postulated that bilirubin (2) conjugation might 
be inhibited by buprenorphine (38) administration, which in turn could result in a greater risk 
of drug-induced jaundice (King, 2000). However, UGT1A1 presents a buprenorphine-binding 
domain that is distinct from that of bilirubin (2). It seems therefore unlikely that buprenorphine 
(38) administration results in higher bilirubin (2) concentrations that could trigger jaundice 
(Rios, 2002). 
 
Hecogenin (52). A recent study performed by Uchaipichat and coworkers revealed that 
hecogenin is presumably a selective inhibitor for UGT1A4 (Uchaipichat, 2006). The inhibitory 
activity of hecogenin was assessed toward ten human recombinant UGT isoforms using 
trifluoperazine (7) as a substrate for UGT1A4 and 4-methylumbelliferone (58) as a substrate 
for all the other isoforms. Trifluoperazine (7) itself was found to be a highly selective 
substrate for UGT1A4. Hecogenin (52) was a potent inhibitor of trifluoperazine (7) 
glucuronidation (IC50 = 1.5 µM). 
 27 
O
O
H
H
H
H
H
OH
O
H
 
N
N
N
N C S
O
 
N
N
O
O2N
F
 
52 53 54 
 
N
N
HO
Cl
N
NN
N
K
 
HO
O
HO
H
H
H
 
O
O
OH
HO
 
O OHO  
55 56 57 58 
 
Trityl derivatives. In a series of nine articles published between 1985 and 1998, various 
compounds, which shared the common structural feature of a trityl (triphenylmethyl) group, 
were investigated for their abilities to inhibit the UGT-catalyzed glucuronidation reaction 
(Fournel, 1985 and 1986; Fournel-Gigleux, 1989; Noort, 1990 and 1991; Said, 1992, 1996 
and 1998; Cano, 1997). The results of these studies are summarized here below: 
 
Based on the initial observation that triphenylacetic acid inhibited microsomal bilirubin (2) 
glucuronidation (Fournel, 1985), a series of six homologous triphenyl carboxylic acids, 
namely triphenylacetic acid, 3,3,3-triphenylpropionic acid, 4,4,4-triphenylbutanoic acid, 5,5,5-
triphenylpentanoic acid, 6,6,6-triphenylhexanoic acid and 7,7,7-triphenylheptanoic acid (59), 
were synthesized and assessed as inhibitors for bilirubin (2) glucuronidation in rat and 
human liver microsomes (Fournel, 1986). The presumably competitive inhibitory activity of 
the homologous tritylcarboxylic acids increased with increasing chain length. The inhibition 
constant for triphenylacetic acid measured in rat liver microsomes was 96 µM, that for 7,7,7-
triphenylheptanoic acid (59) was 5 µM. It was also shown that related compounds lacking the 
trityl group, namely diphenylacetic acid and phenylacetic acid were devoid of significant 
inhibitory activity, suggesting that this functional group represented an essential structural 
feature for the inhibition of UGT1A1. Also triphenylmethane and triphenylmethanol did not 
impair bilirubin (2) glucuronidation indicating the importance of the carboxy group for 
inhibitory activity (Fournel, 1986). 
 
In a further study, Fournel-Gigleux and coworkers confirmed their findings that 7,7,7-
triphenylheptanoic acid (59) is presumably a competitive inhibitor of bilirubin glucuronidation 
for both microsomal and purified bilirubin UGT, displaying Kic values of 12 and 1.6 µM, 
respectively (Fournel-Gigleux, 1989). In this study, the same set of homologous 
triphenylalkanoic acids was assayed (Fournel, 1986). Furthermore, the triphenylalkanoic 
acids 8,8,8-triphenyloctanoic acid and 9,9,9-triphenylnonanoic acid, the ester methyl 7,7,7-
triphenylheptanoate, the methoxy-substituted triphenylalkanoic acid 7-(p-methoxyphenyl)-
7,7-diphenylheptanoic acid, the aliphatic carboxylic acids propanoic acid, butanoic acid, 
pentanoic acid, hexanoic acid, heptanoic acid, octanoic acid and nonanoic acid, and the 
dicarboxylic acids o-di-(6-carboxyhexyl)benzene (60) and p-di-(6-carboxyhexyl)benzene (61) 
were investigated for inhibitory activity. With the exception of 8,8,8-triphenyloctanoic acid, 
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9,9,9-triphenylnonanoic acid and 7-(p-methoxyphenyl)-7,7-diphenylheptanoic acid, the 
compounds did not exert significant inhibition of bilirubin glucuronidation in microsomal 
preparations, confirming the previously published results that the hydrophobic trityl group 
might represent a crucial structural feature for inhibition of bilirubin glucuronidation. The 
isoform selectivity of the best inhibitor in this series, 7,7,7-triphenylheptanoic acid (59), was 
assayed by use of the UGT substrates bilirubin (2), 4-nitrophenol, testosterone (37), and 
ADT (43). 1-Naphthol (9) and testosterone (37) glucuronidation was inhibited 
noncompetitively (Kin = 250 and 58 µM, respectively) and ADT (43) and bilirubin (2) 
glucuronidation was inhibited competitively (Kic = 12 and 65 µM, respectively). However, the 
triphenylalkanoic acid homologues were found to be UGT substrates, i.e., they were actively 
glucuronidated by one or more UGT isoforms, including the best inhibitor in this series, 7,7,7-
triphenylheptanoic acid (59) (Fournel-Gigleux, 1989). Therefore, the inhibitor represents a 
competing substrate for bilirubin (2) glucuronidation rather than a true competitive inhibitor. 
 
The previous finding that the trityl group increased affinity toward UGT enzymes was 
further investigated by two studies conducted by Noort and coworkers (Noort, 1990 and 
1991). In the first study, possible transition state analogues were synthesized, which were 
characterized by a UDP dinucleotide covalently bound to a lipophilic substrate-like moiety 
(Noort, 1990). The inhibitory effects of these compounds were assessed by measuring their 
inhibition of 4-nitrophenol, 1-naphthol (9), bilirubin (2) and testosterone (37) glucuronidation 
in rat liver microsomal fraction. The trityl derivative 2,2,2-triphenylethyl-UDP (62, TPEU) used 
at concentrations of 0.5-1.0 mM significantly inhibited the glucuronidation of the applied 
substrates by 61-81%. Furthermore, also 2-(1-naphthyl)ethyl-UDP (63) was found to be a 
potent inhibitor and its inhibition was competitive toward both UDPGlcA and 4-nitrophenol 
(Kic = 0.1 mM in both cases). Its uridine 5‟-monophosphate (UMP) derivative was not as 
effective in its inhibitory activity as the UDP derivative (Noort, 1990). Based on these results, 
the second study further investigated the inhibitory activity of TPEU by use of the phenolic 
substrates harmol (64) and thyroid hormone T3 (65), and the hydroxamic acid N-hydroxy-2-
acetylaminofluorene (66), N-OH-AAF, in isolated rat hepatocytes (Noort, 1991). It was shown 
that the glucuronidation of harmol (64), T3 (65) and N-OH-AAF (66) was significantly 
decreased by TPEU (62). Interestingly, the inhibition of N-OH-AAF (66) glucuronidation 
resulted in an increased concentration of its corresponding N-sulfate conjugate, the formation 
of which is catalyzed by sulfotransferases. The N-sulfate conjugate displays carcinogenic 
properties owing to its ability to bind covalently to nucleic acids and proteins. Therefore, the 
loss of the glucuronidation pathway due to inhibition by TPEU (62) was compensated for by 
the sulfation pathway, which resulted in significantly increased covalent binding of N-OH-AAF 
(66) to macromolecules of hepatocytes (Noort, 1991). 
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The previous work conducted by Fournel et al. (Fournel, 1986) and Noort et al. (Noort, 
1990) was continued by Said and coworkers (Said, 1992). They studied a series of 
triphenylalkanols and their corresponding triphenylalkyl-UDP derivatives as potential 
inhibitors for UGT-catalyzed 1-naphthol (9), testosterone (37) and bilirubin (2) 
glucuronidation in rat liver microsomes. The results indicated that the alcohols were inhibitors 
of bilirubin (2) glucuronidation with IC50 values ranging from 160-360 µM, whereas the 
corresponding UDP derivatives did not show any significant inhibition (IC50 > 1.0 mM). In 
contrast, the UDP derivatives displayed inhibition of 1-naphthol (9) glucuronidation (IC50 = 
30-446 µM). However, they did not inhibit bilirubin (2) glucuronidation (IC50 > 1000 µM). The 
UDP derivatives and 2,2,2-triphenylethanol as well as 3,3,3-triphenylpropan-1-ol also 
inhibited testosterone (37) glucuronidation (IC50 = 10-141 µM); however 5,5,5-
triphenylpentan-1-ol and 7,7,7-triphenylheptan-1-ol did not significantly impair the UGT-
catalyzed conjugation of this steroid (IC50 > 1000 µM). The best inhibitor of 1-naphthol (9) 
glucuronidation was 7,7,7-triphenylheptan-1-ol-UDP (67) displaying mixed-type inhibition 
toward 1-naphthol (Kim = 30 µM) and competitive inhibition toward the cofactor UDPGlcA (Kic 
= 1.9 µM). 7,7,7-triphenylheptan-1-ol-UDP (67) was a noncompetitive inhibitor of 
testosterone glucuronidation (Kic = 1.7 µM) and a competitive inhibitor of UDPGlcA (Kic = 1.2 
µM; Said, 1992). 
 
In the following study, the IC50 values of phenolphthalein (68) derivatives, 
phenolsulfonphthalein (69) derivatives, triphenylalkanoic acids, and triphenylalkanols were 
determined in rat liver microsomes by the use of bilirubin (2) as the UGT substrate. These 
IC50 values were used to perform a comparative molecular field analysis (CoMFA). This 
analysis allowed for the generation of a geometric model of the binding site for 
phenolphthalein and trityl derivatives (Said, 1996). Further studies revealed that the affinity of 
the inhibitors presumably depends on the pKa value of the corresponding triphenylalkanoic 
acid. Computational studies showed that the trityl derivatives display conformational analogy 
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with (4Z,15Z)-bilirubin, which might explain their inhibitory activity of bilirubin (2) 
glucuronidation (Said, 1998). 
 
Cano and coworkers investigated the inhibitory activity of monomethoxytrityl-UDP 
derivatives bearing different substituents at the uracil moiety. All monomethoxytrityl-UDP 
derivatives inhibited UDPGlcA binding to UGT1*6 with Ki values of 4.4-73 µM. Inhibition was 
either competitive (for bromo- and iodo-substituted uracil) or mixed type (for chloro- and 
fluoro-substituted uracil). Therefore, the type of inhibition seemed to depend on the nature of 
the substituent at the uracil moiety (Cano, 1997). 
 
Trisubstrate transition state analogues. An epimeric trisubstrate UGT transition state 
analogue (70) was synthesized and its inhibitory activity was determined by use of the 
substrates 8-hydroxyquinoline (71) (UGT2B15), propofol (11) (UGT1A8), ethinylestradiol (5) 
(UGT1A1), and 1-naphthol (9) (UGT1A6; Timmers, 1997). Screening assays revealed that 
the compound inhibited the glucuronidation of 8-hydroxyquinoline (71) and propofol (11). 
Ethinylestradiol glucuronidation was inhibited by up to 60% and no inhibition was observed 
for UGT1A6-catalyzed 1-naphthol (9) glucuronidation. Neither IC50 nor Ki values were 
determined. From the presented results it did not become clear, whether the compound 
represented a selective and potent inhibitor of any UGT isoform, let alone whether the two 
epimers were true TS analogues. However, the study showed that the two epimers displayed 
distinct inhibitory activity toward UGT2B15-catalyzed glucuronidation reaction (Timmers, 
1997). 
  
N-acyl phenylaminoalcohol derivatives. Inhibitors of this class contain a lipophilic N-acyl 
phenylaminoalcohol and a hydrophilic uridine moiety connected by different spacer moieties 
(Battaglia, 1995). The ability of these compounds to inhibit the binding of UDPGlcA and of 
the substrate 4-methylumbelliferone (58) to UGT1*6 was measured. The best inhibitor was D-
DPMSU (72) displaying a Kic value of 17 µM (UDPGlcA) and 21 µM (4-methylumbelliferone). 
Based on the results of the inhibitor studies, the role of the spacer moiety to mimic the 
hypothetical alignment of UDPGlcA and aglycone during the assumed transition state was 
investigated (Battaglia, 1995). 
 
Pyrimidine derivatives. A set of substituted pyrimidine bases was investigated in its ability 
to inhibit the UGT-catalyzed 4-nitrophenol and phenolphthalein (68) glucuronidation in rat 
liver microsomes (Naydenova, 1995). The compounds 5-nitrouracil (73) and 4,6-dihydroxy-5-
nitropyrimidine (74) of this set displayed a mixed type inhibition toward 4-nitrophenol (Kim = 
0.11 mM). Both derivatives did not exert significant inhibition toward phenolphthalein (68) 
glucuronidation. 
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To summarize, few true inhibitors for UGTs have been identified and designed to date. 
Furthermore, many studies concerned with inhibitor design did not investigate, whether the 
reported inhibitors were actually substrates of UGTs, which was for example the case for 
some triphenylalkanoic acids. Furthermore, most of the studies failed to address the isoform 
selectivity of these inhibitors. This is probably due to the shortfall to determine the inhibitory 
activity by use of isolated recombinant UGTs. Moreover, the proposed TS analogues lack the 
high affinity and specificity that are generally observed for true TS mimics. In this respect it 
should be mentioned that merely the observation that an inhibitor displays competitive 
competition toward both the substrate- and the cofactor-binding domain is not a sufficient 
criterion for a TS mimic. In this respect, more information about the structural and 
mechanistic features of UGT enzymes is needed to enable the design of true TS analogues. 
Nevertheless, the inhibitors etonitazenyl isothiocyanate (53) and trityl derivatives were 
successfully used to estimate the number of substrate-binding domains present in UGT1A1 
and to gain further information about the bilirubin binding domain, respectively. Hecogenin 
(52) has been identified as a possible isoform-selective inhibitor for UGT1A4. 
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3. Aims of the study 
To date, highly potent and isoform selective inhibitors for UGT enzymes have not been 
designed and even no approach for their rational design has been proposed. 
 
This study was concerned with the identification of structural properties of small substrate 
molecules that control their affinity to the enzymes and the rate at which they are 
glucuronidated. Therefore, the aim of this study was to investigate the fundamental structural 
properties that are well known to regulate potency and efficacy, namely (1) the spatial 
orientation of the nucleophilic group in the substrate molecule and (2) the steric demand in 
the vicinity of this nucleophilic group. These initial studies were designed to provide a rational 
approach to turn high-affinity substrates of UGT2B7 into potent inhibitors by chemically 
modifying their stereochemical and steric features. 
 
The specific aims of the study were 
 
- to investigate stereoselective events during UGT-catalyzed glucuronidation by use of 
appropriate, stereoisomerically pure probe substrates (I); 
 
- to study the influence of steric bulk in the vicinity of the nucleophilic group, which is 
glucuronidated by UGT isoforms, on the affinity and conjugation rate (II); 
 
- to identify high-affinity substrates for UGT2B7 that could serve as lead structures for 
the design of potent and selective inhibitors (II); and 
 
- to chemically modify the identified lead structures to turn them into potent and 
selective inhibitors by chemically modifying their stereochemical and steric properties 
(III, IV). 
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4. Experimental 
A detailed presentation of the materials, analytical, synthetic and biochemical methods can 
be found in the original publications I-IV and in the supporting information for original 
publications I, III and IV. 
 
The supporting information for original publications I, III and IV is not included in this thesis 
book. This material is available from the author or via the Internet at http://pubs.acs.org for 
original publications I (14 pages) and III (45 pages) and at http://www.chemmedchem.org for 
original publication IV (31 pages). 
 
Data analysis (cf. Copeland, 2005; Motulsky and Christopoulos, 2003) 
 
Km and Vmax values were calculated by fitting the data from enzyme assays to the steady-
state velocity equation (Equation 1): 
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For the calculation of inhibition constants, the obtained data were fitted to the equations for 
competitive (Equation 2), mixed-type (Equation 3), noncompetitive (Equation 4) and 
uncompetitive inhibition (Equation 5): 
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The calculation of IC50 values was carried out by plotting data in terms of fractional velocity 
(Equation 6) or %inhibition (Equation 7): 
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The Cheng-Prusoff equation for competitive (Equation 8), mixed-type (Equation 9), 
noncompetitive (Equation 10) and uncompetitive inhibition (Equation 11) allow for the 
conversion of IC50 into the corresponding Ki values: 
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Model selection was carried out by analyzing the statistical parameters by use of the 
corrected Akaike’s information criterion (AICC; Equation 12) and evidence ratio (Equation 13): 
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The characteristic effects of the substrate concentration on the IC50 value for reversible 
enzyme inhibitors can be used to identify the inhibition modalities (Table 1): 
 
 
Table 1. Effect of increasing substrate concentration on IC50 (according to Copeland, 2005) 
Inhibition modality Effect on IC50 
Competitive Increases linearly with increasing [S] 
Mixed-type (α > 1) Increases curvilinearly with increasing [S] 
Mixed-type (α < 1) Decreases curvilinearly with increasing [S] 
Noncompetitive (α = 1) No change with increasing [S] 
Uncompetitive Decreases curvilinearly with increasing [S] 
 
 
Abbreviations. [I] = inhibitor concentration; [S] = substrate concentration; α = modifying factor; AICC = 
corrected Akaike’s information criterion; ΔAICC = difference in AICC values for two competing models; 
h = Hill coefficient; K = number of parameters; Ki = inhibition constant; Kic = competitive inhibition 
constant; Kim = mixed-type inhibition constant; Kin = noncompetitive inhibition constant; Kiu = 
uncompetitive inhibition constant; Km = Michaelis constant; N = number of data points; SS = absolute 
sum of squares; v0 = velocity of uninhibited enzymatic glucuronidation; vi = velocity of inhibited 
enzymatic glucuronidation; Vmax = maximum velocity. 
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5. Results and discussion 
5.1 Simple enantiomers as probe substrates for UGT2B7 and UGT2B17 (I) 
A set of 28 enantiomeric probe substrates comprising rigid and flexible secondary alcohols 
was synthesized from their corresponding ketones by the asymmetric Corey-Bakshi-Shibata 
reduction (Figure 4). 
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Figure 4. Corey-Bakshi-Shibata reduction exemplified for tetralone using (R)- and (S)-2-
(diphenylhydroxymethyl)pyrrolidine (DEANB = borane N,N-diethylaniline complex), and the structures of the 
enantiomerically pure probe substrates. 
 
 
The enantiomerically pure alcohols were subjected to enzymatic glucuronidation assays 
employing the recombinant human UGTs 2B7 and 2B17. Both UGTs displayed 
stereoselective glucuronidation, favoring the conjugation of the (R)-enantiomers over their 
mirror-image compounds (Table 2). The enantiomers of the chiral compounds displayed 
similar affinities to the binding-domains of UGT2B7 and UGT2B17 (Table 2). 
 
The spatial orientation of the nucleophilic hydroxy group determined the glucuronidation 
rate, whereas the configuration at the asymmetric C-atom did not significantly influence the 
affinity to the binding-domain of UGT2B7 and UGT2B17. These results show that the 
glucuronidation rate may be controlled by the stereochemical properties of the chiral 
substrate molecules. 
 
Interestingly, eudismic analysis revealed that the configuration at the stereogenic center 
of the enantiomeric probe substrates determined the rate of the UGT2B17-catalyzed 
conjugation reaction in agreement with Pfeiffer‟s rule (eudismic activity quotient = 0.83; cf. 
page 23). This finding indicated a significant participation of the element of chirality during 
the UGT2B17-catalyzed glucuronidation reaction. In contrast, no such pattern was found for 
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the affinity to the binding-domain of both UGTs, indicating that the element of chirality had 
presumably no significant influence on the affinity of the enantiomers to the UGT isoforms. 
 
 
Table 2. Eudismic ratios for the enantiomeric probe substrates (cf. original publication I). 
 UGT2B7  UGT2B17 
compound 
eudismic ratio 
(velocity) 
eudismic ratio 
(IC50) 
 
eudismic ratio 
(velocity) 
eudismic ratio 
(IC50) 
1 8.29 1.45  43.7 1.55 
2 14.5 1.21  59.7 1.18 
3 58.1 1.24  45.1 1.33 
4 8.38 1.09  17.5 1.41 
5 6.57 1.05  256 1.47 
6 6.38 1.02  50.2 1.40 
7 38.9 1.24  131 1.12 
8 2.72 1.87  11.4 1.05 
9 5.79 1.77  14.3 1.12 
10 6.86 1.37  109 1.49 
11 1.10 1.65  14.0 1.38 
12 7.54 1.33  13.9 1.14 
13 4.56 1.55  8.22 1.16 
 
 
The results of this study revealed that it may be possible to control the rate of the 
UGT2B7- and UGT2B17-catalyzed glucuronidation by changing the configuration of the C-
atom bearing the nucleophilic hydroxy group. 
 
5.2 Epimeric tricyclic sesquiterpenols as probe substrates for UGT2B7 (II) 
The epimers of three tricyclic sesquiterpenols, namely globulol/ epiglobulol, cedrol/ epicedrol 
and longifolol/ isolongifolol were subjected to glucuronidation and inhibition assays. The 
diastereomeric alcohols exhibited nearly identical affinities to the substrate-binding domain of 
UGT2B7, whereas the rates of the UGT2B7-catalyzed conjugation reaction were markedly 
different (Table 3). 
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The results of the glucuronidation assays revealed that there were large differences in 
the rates at which the epimeric alcohols were conjugated. This finding indicated that the 
spatial arrangement of the hydroxy group controlled the rate of the UGT2B7-catalyzed 
reaction. Interestingly, the Kic values of the epimeric sesquiterpenols were highly similar 
indicating that the spatial orientation of the nucleophilic hydroxy group had no significant 
influence on the affinity to the substrate-binding domain of UGT2B7. Longifolol and 
isolongifolol displayed the highest affinities toward the enzyme with Kic values of 23 and 26 
nM, respectively. 
 
 
 
 37 
Table 3. Inhibition constants, amounts of formed glucuronide, and corresponding eudismic ratios for the epimeric 
sesquiterpenols. 
compound 
Kic 
(µM) 
eudismic ratio
 
(Kic) 
formed glucuronide 
(pmol) 
eudismic ratio 
(formed glucuronide) 
globulol 5.4 
1.4 
789 ± 55 
> 98 
epiglobulol 4.0 < 8 
cedrol 0.15 
1.4 
31 ± 1.6 
> 3.9 
epicedrol 0.21 < 8 
longifolol 0.023 
1.1 
810 ± 70 
12 
isolongifolol 0.026 65 ± 4.2 
 
 
To assess the influence of steric bulk in the vicinity of the nucleophilic hydroxy group of 
longifolol and its epimer isolongifolol, a methyl group was introduced to the side chain of 
these sesquiterpenols (Figure 5). 
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H
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H
CH3MgI
Et2O
0 °C, 1 h
H
OH
longifolol
isolongifolol
1
2  
Figure 5. Synthesis of the methyl substituted longifolol (1) and isolongifolol (2) derivatives (IBX = 2-iodoxybenzoic 
acid, DMSO = dimethylsulfoxide). 
 
 
As a result, the rate of the UGT2B7-catalyzed reaction was decreased by more than 
88%. This finding indicated that the rate of the UGT2B7-catalyzed glucuronidation of 
longifolol and isolongifolol was significantly controlled by both stereochemical and steric 
features. Therefore, true inhibitors may be designed by increasing the steric demand close to 
the asymmetric C-atom that bears the nucleophilic hydroxy group to prevent glucuronidation. 
Considering the high affinity exerted by the tricyclic sesquiterpenols, these compounds 
served as lead structures for the design of potent inhibitors for UGT2B7 in the subsequent 
studies. 
 
5.3 Inhibitors for UGT2B7 derived from longifolol and isolongifolol (III, IV) 
A set of 76 derivatives of the epimeric tricyclic sesquiterpenols longifolol and isolongifolol 
was synthesized and subjected to inhibition and glucuronidation assays employing the 
human UGT2B7 (Figure 6; the synthesis schemes of the longifolol and isolongifolol 
derivatives are given in the original publications III and IV and the corresponding supporting 
information). The compounds are related as stereoisomers (epimers, diastereomers), and 
geometric isomers (E-, Z-isomers), and they bear different functional groups, namely 
hydroxy, carboxy, phosphono, ester, amino, and alkyl groups of varying steric demand. 
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Figure 5. The synthesized stereoisomerically pure isolongifolol and longifolol derivatives of the original 
publications (III) and (IV), respectively. 
 
 
Furthermore, the spatial orientation of these functional groups is different because they 
are either endo-positioned (isolongifolol derivatives) or exo-oriented (longifolol derivatives). 
The absolute configuration of the epimeric compounds was assigned by 2D NMR 
experiments (gHSQC, gNOESY) in agreement with crystallographic data. 
H
OH
H
 
H
HO
H
 
compound 26b of original publication III compound 16b of original publication IV 
 
The phenyl-substituted secondary alcohols 26b of original publication III and 16b of 
original publication IV displayed the highest affinity toward UGT2B7 and their inhibitory 
dissociation constants were 18 and 0.91 nM, respectively. The phenyl-substituted longifolol 
and isolongifolol derivatives were not glucuronidated by UGT2B7 and other hepatic UGT 
enzymes, presumably due to the high steric hindrance exerted by their bulky phenyl 
substituent. Their inhibitory activities toward 14 other UGT isoforms of subfamily 1A and 2B 
were determined and the data indicated that the tricyclic secondary alcohols 26b and 16b 
were highly selective for UGT2B7 displaying true selectivities of >1000 and >20000, 
respectively. This data indicated that the stereochemical features of the inhibitors may also 
influence their selectivity for UGT2B7. 
 
The key function of the phenyl group was to increase the steric hindrance in vicinity of the 
hydroxy group and therefore to decrease the accessibility to this nucleophilic functionality 
thus preventing enzymatic glucuronidation. The hydroxy group had presumably no significant 
effect on the formation of the enzyme-inhibitor complex, indicating that there was no 
markedly attractive interaction to the binding site of UGT2B7. The hydroxy group was merely 
retained to promote the solubility of the compound. 
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6. Conclusion 
This study showed that UGT2B7 and UGT2B17 were able to display high levels of 
stereoselective glucuronidation. Especially UGT2B17 was highly selective for glucuronidating 
the (R)-enantiomers of the synthesized stereoisomerically pure probe substrates. 
Interestingly, the spatial orientation of the nucleophilic hydroxy group did not significantly 
alter their affinity to the enzymes. This finding indicated that the hydroxy group, i.e. the very 
site of enzymatic glucuronidation, did not contribute to the affinity to the substrate binding 
site, presumably resulting either from no or only very weak interactions to amino acid 
residues in the substrate binding domain. 
 
These results have been confirmed by assaying epimeric sesquiterpenols with the key 
enzyme involved in drug glucuronidation, UGT2B7. In agreement with the previous results, 
large differences in the formation of the corresponding glucuronides have been observed. 
However, the UGT2B7 affinities of the epimeric substrates were highly similar, although the 
physicochemical properties of these epimers are different. Consistently, the spatial 
orientation of the nucleophilic hydroxy group did not seem to control the affinity to the 
enzymes but the rate at which they were glucuronidated. Taken together, these preliminary 
results suggested that the affinity to the substrate binding domain was predominantly 
governed by lipophilic rather than hydrophilic interactions. 
 
Further studies revealed that the glucuronidation rate of chiral substrates might be 
controlled by altering the steric demand in vicinity of the nucleophilic group in the substrate 
molecule. In this respect, the glucuronidation of the lead structure longifolol and isolongifolol 
was reduced by the introduction of methyl groups in vicinity of the nucleophilic hydroxy 
group. This led to the assumption that by controlling stereochemical and steric features, 
enzymatic glucuronidation might be prevented, and, hence, UGT substrates might be turned 
into true inhibitors of UGT isoforms. 
 
Longifolol and isolongifolol were identified as high-affinity substrates of UGT2B7 which 
displayed high selectivity to this enzyme with respect to their affinity. However, the structural 
features responsible for their high selectivity for UGT2B7 remained unclear because the full-
length crystal structures or at least those of the substrate binding domains of the different 
UGT isoforms remain to be resolved. Therefore, it seems difficult to decipher the structural 
properties that result in this high selectivity for UGT2B7 in the absence of detailed structural 
data of the enzyme. 
 
However, the identification of the potent and selective UGT2B7 substrates longifolol and 
isolongifolol enabled the design of selective inhibitors for this UGT isoform. By introducing 
bulky phenyl groups to the sesquiterpenols, glucuronidation was prevented, whereas the 
high affinity of these derivatives remained. Interestingly, the stereochemical features seemed 
to regulate also the isoform selectivity because the true selectivities of the phenyl derivatives 
26b and 16b differed by a factor of approximately 20. It might therefore be asked, whether or 
not stereochemistry also alters the isoform selectivity of chiral inhibitors and substrates. 
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